Victory Capital Management Inc. Trims Stake in Amedisys, Inc. (NASDAQ:AMED)

Victory Capital Management Inc. lessened its holdings in Amedisys, Inc. (NASDAQ:AMED) by 2.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,088 shares of the health services provider’s stock after selling 182 shares during the quarter. Victory Capital Management Inc.’s holdings in Amedisys were worth $553,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Blue Trust Inc. grew its holdings in shares of Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after buying an additional 124 shares during the last quarter. HBW Advisory Services LLC bought a new position in Amedisys during the fourth quarter valued at approximately $38,000. Versant Capital Management Inc lifted its position in Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after purchasing an additional 183 shares during the period. KBC Group NV bought a new position in Amedisys during the third quarter valued at approximately $63,000. Finally, Venturi Wealth Management LLC lifted its position in Amedisys by 397.4% during the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after purchasing an additional 779 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Stock Down 0.4 %

AMED opened at $92.38 on Friday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The company has a market capitalization of $3.03 billion, a PE ratio of 36.66, a PEG ratio of 1.78 and a beta of 0.76. The firm’s 50 day simple moving average is $92.21 and its two-hundred day simple moving average is $92.63.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. As a group, equities analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.

Analysts Set New Price Targets

Separately, Stephens restated an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.